Cargando…

Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events

AIMS: Transforming growth factor-beta (TGF-β) exists in three isoforms TGF-β1, -β2, and -β3. TGF-β1 has been suggested to be important for maintaining plaque stability, yet the role of TGF-β2 and -β3 in atherosclerosis remains to be investigated. This study explores the association of the three isof...

Descripción completa

Detalles Bibliográficos
Autores principales: Edsfeldt, Andreas, Singh, Pratibha, Matthes, Frank, Tengryd, Christoffer, Cavalera, Michele, Bengtsson, Eva, Dunér, Pontus, Volkov, Petr, Karadimou, Glykeria, Gisterå, Anton, Orho-Melander, Marju, Nilsson, Jan, Sun, Jiangming, Gonçalves, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478752/
https://www.ncbi.nlm.nih.gov/pubmed/37200403
http://dx.doi.org/10.1093/cvr/cvad079
_version_ 1785101419257266176
author Edsfeldt, Andreas
Singh, Pratibha
Matthes, Frank
Tengryd, Christoffer
Cavalera, Michele
Bengtsson, Eva
Dunér, Pontus
Volkov, Petr
Karadimou, Glykeria
Gisterå, Anton
Orho-Melander, Marju
Nilsson, Jan
Sun, Jiangming
Gonçalves, Isabel
author_facet Edsfeldt, Andreas
Singh, Pratibha
Matthes, Frank
Tengryd, Christoffer
Cavalera, Michele
Bengtsson, Eva
Dunér, Pontus
Volkov, Petr
Karadimou, Glykeria
Gisterå, Anton
Orho-Melander, Marju
Nilsson, Jan
Sun, Jiangming
Gonçalves, Isabel
author_sort Edsfeldt, Andreas
collection PubMed
description AIMS: Transforming growth factor-beta (TGF-β) exists in three isoforms TGF-β1, -β2, and -β3. TGF-β1 has been suggested to be important for maintaining plaque stability, yet the role of TGF-β2 and -β3 in atherosclerosis remains to be investigated. This study explores the association of the three isoforms of TGF-β with plaque stability in the human atherosclerotic disease. METHODS AND RESULTS: TGF-β1, -β2, and -β3 proteins were quantified in 223 human carotid plaques by immunoassays. Indications for the endarterectomy were: symptomatic carotid plaque with stenosis >70% or without symptoms and >80% stenosis. Plaque mRNA levels were assessed by RNA sequencing. Plaque components and extracellular matrix were measured histologically and biochemically. Matrix metalloproteinases and monocyte chemoattractant protein-1 (MCP-1) was measured with immunoassays. The effect of TGF-β2 on inflammation and protease activity was investigated in vitro using THP-1 and RAW264.7 macrophages. Patients were followed longitudinally for cardiovascular (CV) events. TGF-β2 was the most abundant isoform and was increased at both protein and mRNA levels in asymptomatic plaques. TGF-β2 was the main determinant separating asymptomatic plaques in an Orthogonal Projections to Latent Structures Discriminant Analysis. TGF-β2 correlated positively to features of plaque stability and inversely to markers of plaque vulnerability. TGF-β2 was the only isoform inversely correlated to the matrix-degrading matrix metalloproteinase-9 and inflammation in the plaque tissue. In vitro, TGF-β2 pre-treatment reduced MCP-1 gene and protein levels as well as matrix metalloproteinase-9 gene levels and activity. Patients with plaques with high TGF-β2 levels had a lower risk to suffer from future CV events. CONCLUSIONS: TGF-β2 is the most abundant TGF-β isoform in human plaques and may maintain plaque stability by decreasing inflammation and matrix degradation.
format Online
Article
Text
id pubmed-10478752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104787522023-09-06 Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events Edsfeldt, Andreas Singh, Pratibha Matthes, Frank Tengryd, Christoffer Cavalera, Michele Bengtsson, Eva Dunér, Pontus Volkov, Petr Karadimou, Glykeria Gisterå, Anton Orho-Melander, Marju Nilsson, Jan Sun, Jiangming Gonçalves, Isabel Cardiovasc Res Original Article AIMS: Transforming growth factor-beta (TGF-β) exists in three isoforms TGF-β1, -β2, and -β3. TGF-β1 has been suggested to be important for maintaining plaque stability, yet the role of TGF-β2 and -β3 in atherosclerosis remains to be investigated. This study explores the association of the three isoforms of TGF-β with plaque stability in the human atherosclerotic disease. METHODS AND RESULTS: TGF-β1, -β2, and -β3 proteins were quantified in 223 human carotid plaques by immunoassays. Indications for the endarterectomy were: symptomatic carotid plaque with stenosis >70% or without symptoms and >80% stenosis. Plaque mRNA levels were assessed by RNA sequencing. Plaque components and extracellular matrix were measured histologically and biochemically. Matrix metalloproteinases and monocyte chemoattractant protein-1 (MCP-1) was measured with immunoassays. The effect of TGF-β2 on inflammation and protease activity was investigated in vitro using THP-1 and RAW264.7 macrophages. Patients were followed longitudinally for cardiovascular (CV) events. TGF-β2 was the most abundant isoform and was increased at both protein and mRNA levels in asymptomatic plaques. TGF-β2 was the main determinant separating asymptomatic plaques in an Orthogonal Projections to Latent Structures Discriminant Analysis. TGF-β2 correlated positively to features of plaque stability and inversely to markers of plaque vulnerability. TGF-β2 was the only isoform inversely correlated to the matrix-degrading matrix metalloproteinase-9 and inflammation in the plaque tissue. In vitro, TGF-β2 pre-treatment reduced MCP-1 gene and protein levels as well as matrix metalloproteinase-9 gene levels and activity. Patients with plaques with high TGF-β2 levels had a lower risk to suffer from future CV events. CONCLUSIONS: TGF-β2 is the most abundant TGF-β isoform in human plaques and may maintain plaque stability by decreasing inflammation and matrix degradation. Oxford University Press 2023-05-18 /pmc/articles/PMC10478752/ /pubmed/37200403 http://dx.doi.org/10.1093/cvr/cvad079 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Edsfeldt, Andreas
Singh, Pratibha
Matthes, Frank
Tengryd, Christoffer
Cavalera, Michele
Bengtsson, Eva
Dunér, Pontus
Volkov, Petr
Karadimou, Glykeria
Gisterå, Anton
Orho-Melander, Marju
Nilsson, Jan
Sun, Jiangming
Gonçalves, Isabel
Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
title Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
title_full Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
title_fullStr Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
title_full_unstemmed Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
title_short Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
title_sort transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478752/
https://www.ncbi.nlm.nih.gov/pubmed/37200403
http://dx.doi.org/10.1093/cvr/cvad079
work_keys_str_mv AT edsfeldtandreas transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT singhpratibha transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT matthesfrank transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT tengrydchristoffer transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT cavaleramichele transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT bengtssoneva transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT dunerpontus transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT volkovpetr transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT karadimouglykeria transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT gisteraanton transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT orhomelandermarju transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT nilssonjan transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT sunjiangming transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents
AT goncalvesisabel transforminggrowthfactorb2isassociatedwithatheroscleroticplaquestabilityandlowerriskforcardiovascularevents